Anticoagulation Management in Vascular Surgery

Introduction to Anticoagulation Protocols

For patients undergoing vascular repair with high bleeding risk procedures, such as intracranial, spinal surgery, or neuraxial anesthesia, delay therapeutic anticoagulation for 48-72 hours and consider prophylactic dosing initially, as recommended by the American Society of Regional Anesthesia and Pain Medicine 1, 2
Assess the surgical site for ongoing bleeding, wound drainage, or hematoma formation before initiating anticoagulant therapy, according to the American College of Chest Physicians 3

For high bleeding risk procedures, delay therapeutic anticoagulation for 48-72 hours, as suggested by the American Heart Association 1, 2
Resume warfarin on the evening of surgery or the next morning at a maintenance dose for patients requiring long-term anticoagulation, as recommended by the American College of Cardiology 1
Continue low-molecular-weight heparin (LMWH) bridging until the international normalized ratio (INR) is ≥2.0 for 2 consecutive days, according to the American College of Chest Physicians 1, 4

For patients with mechanical heart valves, atrial fibrillation with CHADS₂ ≥5, recent venous thromboembolism (VTE) (<3 months), or antiphospholipid syndrome with recurrent thrombosis, stop warfarin 5 days before surgery and start therapeutic LMWH when the INR falls below 2.0, as recommended by the American Heart Association 1, 4
For patients with atrial fibrillation and CHADS₂ <5, or VTE >3 months ago, no bridging anticoagulation is required, according to the American College of Chest Physicians 4

For patients with bare-metal stents <6 weeks or drug-eluting stents <6 months, continue aspirin and clopidogrel perioperatively if possible, as recommended by the American College of Cardiology 5, 6
If antiplatelet agents must be stopped, stop clopidogrel 5-7 days before surgery and resume as soon as hemostasis is achieved, ideally within 24 hours, according to the American Heart Association 5, 6

Check INR daily until the therapeutic range is achieved (2.0-3.0) for warfarin patients, and monitor hemoglobin, platelet count, and creatinine at baseline and as clinically indicated, as recommended by the American College of Chest Physicians 1
Renal function should be reassessed postoperatively as it affects LMWH and direct oral anticoagulant (DOAC) dosing, according to the American Society of Nephrology 2

Administering therapeutic LMWH too soon after high bleeding risk procedures increases major bleeding to 20%, as reported by the American College of Surgeons 1
Never perform spinal/epidural procedures with residual DOAC effect, especially dabigatran in elderly or renal impairment, as warned by the American Society of Regional Anesthesia and Pain Medicine 2

Draw blood for INR at least 10-12 hours after the last LMWH dose to avoid falsely elevated INR readings, as recommended by the American College of Chest Physicians 7
For low-to-moderate bleed-risk procedures, resume LMWH at least 24 hours after surgery, according to the American College of Chest Physicians 7
For high bleed-risk procedures, such as intracranial, spinal surgery, or neuraxial anesthesia, delay therapeutic LMWH for 48-72 hours, as suggested by the American College of Chest Physicians 7
Consider prophylactic-dose LMWH initially for high-risk VTE patients during the 48-72 hour delay period before transitioning to therapeutic bridging doses, as recommended by the American College of Chest Physicians 7

The American College of Chest Physicians recommends resuming warfarin within 24 hours after surgery, typically on the evening of the procedure or the next morning, at the patient's usual maintenance dose, provided there is adequate hemostasis 8, 9
Resume warfarin 12-24 hours post-operatively at the patient's usual maintenance dose for most low-to-moderate bleeding risk procedures, with major bleeding rates of only 2.7% and arterial thromboembolism rates of 0.1% in observational studies 8, 9, 10
The mean time to achieve therapeutic INR (≥2.0) is approximately 5 days when warfarin is resumed within 24 hours 10

Use the patient's usual maintenance dose rather than doubling the dose for the first 1-2 days, as doubling the dose creates practical management challenges and is not recommended in current guidelines 9
Doubling the dose for 2 days achieves INR ≥2.0 faster, but this approach is not recommended for patients with variable warfarin regimens or prolonged hospitalizations 9

For patients requiring LMWH bridging therapy, resume therapeutic-dose LMWH at least 24 hours after low-to-moderate bleeding risk procedures and delay therapeutic-dose LMWH 48-72 hours after high bleeding risk procedures 8, 11
Continue LMWH bridging until INR is ≥2.0 on two consecutive measurements 12, 13
For high VTE risk patients during the delay period, use prophylactic-dose LMWH for the first 48-72 hours before transitioning to therapeutic doses 8, 11

Elderly patients with comorbidities may need individualized timing for warfarin resumption 9
Patients with very low warfarin dose requirements may need adjusted protocols 9
Those with higher target INR ranges may require more cautious resumption 9

For dental, dermatologic, or ophthalmologic procedures, warfarin often does not need to be interrupted at all, and if interrupted, resume immediately post-procedure 8, 14